Wegovy and Ozempic maker Novo Nordisk has agreed to buy Cardior Pharmaceuticals for $1.11 billion. The acquisition is part of Novo Nordisk’s larger strategy to build a portfolio of therapies in cardiovascular disease.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
